Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which sedation works best for stent removal? new study compares options

NCT ID NCT07580768

Symptom relief Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested three sedation approaches for removing a Double-J ureteral stent, a common procedure. Sixty adults received either propofol alone, propofol plus dexmedetomidine, or propofol plus midazolam. Researchers measured total propofol use and sedation levels to find the most effective and safe combination.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Propofol, dexmedetomidine, midazolam
What this could lead to
If successful, this could identify a safer or more effective sedation combination for a common urological procedure.
What could go wrong
This is a small, completed trial with 60 participants, so results may not apply broadly. Sedation risks like breathing problems or low blood pressure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Nov 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age from 21 to 65 years. * Both sex. * Physical status of the patients were from I-III according to American Society of Anesthesiologists (ASA). * Patients underwent Double-J ureteral stent removal. Exclusion Criteria: * Symptoms of lower urinary tract infection. * Stenosis of the urethra during cystoscopy. * Renal impairment (serum creatinine \>1.5 mg/dL). * Chronic pain syndrome. * Mental disorder and difficulty in communication. * History of chronic use of sedatives, alcohol and narcotics. * Bradycardia (heart rate less than 50 beats per minute). * Systolic blood pressure less than 90 mm Hg. * Taking a sedative or analgesic 24 hours before surgery. * Body mass index (BMI) equal or over 35 kg/m2. * History of allergy to one of the drugs used in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dexmedetomidine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dexmedetomidine Double-J ureteral stent Midazolam Propofol Sedation

Contacts and locations

Locations

  • Tanta University

    Tanta, El-Gharbia, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.